Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited has announced an update on its ongoing share buy-back program, with 149,712 ordinary shares purchased on the previous day through JP Morgan Securities Australia Limited. This buy-back initiative is part of CSL’s strategy to optimize its capital structure and enhance shareholder value, reflecting the company’s robust financial health and commitment to returning capital to its investors.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative biotherapies and influenza vaccines. The company is a leader in its field, providing essential medical solutions to improve patient health and well-being globally.
Average Trading Volume: 1,007,797
Technical Sentiment Signal: Sell
Current Market Cap: A$100.9B
See more insights into CSL stock on TipRanks’ Stock Analysis page.